Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
Authors' conclusion
Twelve months of dapagliflozin was associated with a significant reduction in liver fat as measured by MRI-PDFF compared to placebo; this effect was independent of weight loss and other known beneficial metabolic effects of SGLT2 inhibition.
Study context
- Population
- Patients with T2D; 76% had hepatic steatosisrandomized
- Participants
- 56 patients
- Comparison
- Dapagliflozin 10 mg vs placebo
- Primary endpoint
- Change in liver fat (MRI-PDFF)
- Follow-up
- 12 months
Methodological detailsmediation analysis
- Mediation analysis
Primary result
As reported in the abstract
Change in liver MRI-PDFF
Dapagliflozin
−3.7%
Placebo
0.5%
P = 0.001
Further findings
| Outcome | Dapagliflozin | Placebo | P value |
|---|---|---|---|
| Change in body weight · 12 months | −3.84 kg | −1.42 kg | P = 0.015 |
| Change in HbA1c · 12 months | −0.52 | 0.11 | P = 0.012 |
Original publication
Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes. Obesity (Silver Spring). Published 2 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →